Cost-Effectiveness of PDL1 Based Test-And-Treat Strategy with Pembrolizumab as the 1st Line Treatment for NSCLC in Hong Kong

被引：0

作者：

Loong, H. ^{[1
]}

Huang, M. ^{[2
]}

Wong, C. ^{[3
]}

Leung, L. ^{[1
]}

Burke, T. ^{[4
]}

Chandwani, S. ^{[4
]}

Law, A. ^{[5
]}

Tan, S. C. ^{[6
]}

机构：

[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China

[2] Merck & Co Inc, Ctr Observat & Real World Evidence, N Wales, PA USA

[3] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China

[4] Merck & Co Inc, Ctr Observat & Real World Evidence, Rahway, NJ 07065 USA

[5] Merck Sharp & Dohme Ltd, Hong Kong, Peoples R China

[6] Merck Sharp & Dohme Asia Pacific, Singapore, Singapore

来源：

关键词：

cost effectiveness; BTS in Hong Kong; pembrolizumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-050

引用

页码：S1912 / S1912

页数：1